Data Readout

Fractyl's Revita device faces pivotal weight-maintenance test this Q4

REMAIN-1's sham-controlled data will show whether duodenal ablation can hold weight loss after patients stop tirzepatide, a gap no drug or device has yet closed.

By AppliedXLJuly 13, 2026Trial NCT06484114

Executive Summary

Fractyl Health is heading toward a sham-controlled pivotal readout that will test whether a one-time endoscopic procedure can hold weight loss after patients come off tirzepatide, a question current obesity therapy has not had to answer at scale before.
The sponsor's own earlier-stage cohort already showed the effect scaling with procedural dose and with how much weight patients lost before the procedure, a dose-response pattern that gives the pivotal design a specific, prespecified effect to confirm rather than a first look at an untested hypothesis.
No other clinical-stage program is testing a procedural device for this specific maintenance use; the field around the trial is built entirely of GLP-1 drugs and behavioral interventions, which changes what patients do after stopping a drug, not what a device can do instead of one.
The trial's own completion date sits months past the guided data window, a gap that is normal for a registrational device study reporting an early topline cut ahead of full primary completion, and the sponsor has repeated the same quarter through multiple disclosures since March.

The catalyst

REMAIN-1 (NCT06484114) is a randomized, sham-controlled pivotal study enrolling 315 adults with obesity who lost at least 15% of their body weight on tirzepatide and then stopped the drug. The trial randomizes patients to Revita, an endoscopic procedure that ablates a length of duodenal mucosa, or a sham procedure, and follows them to see whether Revita maintains that weight loss without continued pharmacotherapy. Fractyl completed randomization in the Pivotal Cohort and said topline 6-month data are expected in early Q4 2026, with a De Novo marketing application to the FDA targeted for late Q4 2026 if the data are positive. NCT06484114+1

Probability of Success

Endpoint Met91%

Completes100%

Clinical Significance5%

Regulatory96%

The supporting evidence

Fractyl has already reported post-hoc analyses from the trial's earlier Midpoint Cohort that inform what the Pivotal readout is powered to show. Among 45 midpoint patients, the analysis found a statistically significant correlation between the length of duodenal ablation and weight maintenance in the Revita arm (n=29, p=0.048), and among patients with above-median GLP-1-induced weight loss before randomization, a 70% reduction in weight regain versus sham that widened from month 1 to month 6 (p=0.004). Chief Executive Harith Rajagopalan said the therapy "appears to work very much like a drug: the effect of weight maintenance is larger in patients with greater GLP-1 weight loss and in those who receive longer lengths of duodenal ablation," and that the Pivotal Cohort "was prospectively designed and statistically powered to demonstrate Revita's effect across these dimensions". Fractyl

Competitive frame

No peer trial in the obesity field shares Revita's mechanism or modality. The nearest activity in the space comes from GLP-1 receptor agonists such as semaglutide and tirzepatide in ongoing Phase 4 studies, and from a behavioral-treatment trial, none of which test a procedural substitute for continued drug therapy. That absence of a direct comparator means REMAIN-1 is not competing against a rival program for the same claim; it is testing a modality question the field has not yet had answered. For the readout to be informative rather than merely descriptive, the sham-adjusted effect on weight maintenance would need to persist through the full 6-month follow-up at a magnitude consistent with what the Midpoint Cohort's dose-response analysis implied.

Operational context

The trial's primary completion date moved from September 30, 2026 to February 15, 2027 in a registry update logged March 3, 2026, a change of about five months. That shift affects when the full primary-endpoint dataset locks, not the topline 6-month cut the sponsor has guided to for Q4 2026; Fractyl has repeated the same Q4 2026 window in disclosures dated as recently as June 4, 2026. Enrollment has held flat at the original target of 315 with no growth or reduction, which the trial's own operational thresholds treat as a routine, unremarkable pattern for a study that has moved from recruiting to Active, not recruiting on schedule. NCT06484114+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.